Objective: To assess the clinicopathologic factors influencing survival in patients with metastatic urothelial carcinoma undergoing salvage chemotherapy. Methods: A retrospective review was conducted on cases of metastatic urothelial carcinoma who underwent cisplatin-based salvage chemotherapy at our institution between April 2003 and July 2011. The association of various clinicopathologic factors with survival was assessed. Survival curves were constructed by the Kaplan -Meier method. A log-rank test for univariate analysis and a Cox proportional hazards model for multivariate analysis were used. Results: Eighty-three cases were identified in the study. Among them, 64 patients were dead during the follow-up. The median survival was 14.6 months. Multivariate analysis evaluating variables at the start of chemotherapy demonstrated that liver metastasis, performance status score 2 and leukocyte counts 8000/ml were significant predictive factors for poor outcome. Based on these three pre-induction variables, a risk model predicting the overall survival from the initiation of chemotherapy was constructed, which classified patients into three groups with significantly different overall survival (P , 0.0001). Additionally, factors after induction of chemotherapy were studied, and poor response for chemotherapy and absence of focal treatment for metastatic lesions were also significantly associated with poorer survival. Conclusions: Liver metastasis, poor performance status and higher leukocyte counts were independent poor prognostic indicators for metastatic urothelial carcinoma. Our risk classification enables an accurate prediction of survival that can be useful in deciding which patients are likely to benefit from salvage chemotherapy.
INTRODUCTION
In 2008, more than 380 000 patients worldwide were estimated to be diagnosed with urothelial carcinoma (UC) resulting in more than 150 000 deaths (1) . In Japan, UC is the sixth most commonly diagnosed cancer and accounts for 7000 deaths annually (2) . Metastatic UC is known to be intractable and rarely has the median survival of untreated cases exceeding 3-6 months (3). Even after the introduction of cisplatin-based chemotherapy, the median survival still remains at 15 months (4, 5) . Although a few cases achieve a long-term survival, studies are lacking to evaluate the predictive and prognostic factors in metastatic UC. The present retrospective study was conducted to assess the clinicopathologic factors influencing survival in cases with metastatic UC undergoing salvage chemotherapy.
PATIENTS AND METHODS
Cases of metastatic UC who underwent cisplatin-based salvage chemotherapy at our institution between April 2003 and July 2011 were reviewed. The chemotherapy included three regimens: MVAC (methotrexate/vinblastine/doxorubicin/cisplatin), GC (gemcitabine/cisplatin) and DIP (docetaxel/ ifosfamide/cisplatin) (6) . All patients underwent evaluations that included routine blood test, chest X-ray and CT scan every 1 -6 months. The charts were reviewed thoroughly and the status of each patient was assessed by office visit and/or phone call to the patient. Follow-up information was obtained as of September 2012.
Clinicopathologic parameters were assessed at the start of chemotherapy and, additionally, factors after induction of chemotherapy were also analyzed. Estimated glomerular filtration rate was calculated using the revised formula for Japanese (7) . Focal treatment for metastatic lesions was defined as either metastasectomy or radiotherapy intended to eliminate the metastatic site of more than 50 Gray. The maximum effect of chemotherapy was evaluated according to the RECIST guideline (8) . The overall survival was calculated from the initiation of chemotherapy to death or last follow-up. Survival curves were drawn using the Kaplan -Meier method. Log-rank test and Cox proportional hazards model were used for univariate and multivariate analyses. All statistical analyses were carried out using JMP version 9.0.2 (SAS Institute, Cary, NC, USA). A P value of ,0.05 was considered significant.
RESULTS
Eighty-three cases were identified in the current study. Table 1 lists the clinical and pathologic characteristics of the patients. There were 69 males and 14 females with a median age of 67 years (range: 36 -82 years) at the start of chemotherapy. Primary tumor sites were bladder in 36 patients, upper urinary tract in 40 patients and both in 7 patients. First-line regimens were MVAC in 30 patients, GC in 48 patients and DIP in 5 patients. Among them 64 (77.1%) were dead during the follow-up. The median survival time was 14.6 months (95% confidence interval 11.6-21.5 months, Fig. 1 ). 
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Univariate analysis of the parameters at the start of chemotherapy showed that age 67 years, Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 2, visceral metastasis, bone metastasis, liver metastasis, multiple organ metastases, metastasis to other site than lymph node, leukocyte counts 8000/ml and serum C-reactive protein (CRP, 0.3 mg/dl) were associated with poor outcome (Table 2) .
A Cox proportional hazards model demonstrated that liver metastasis [hazard ratio (HR) 12.65, P , 0.0001], ECOG PS (HR 7.099, P ¼ 0.0182) and leukocyte counts (HR 2.890, P ¼ 0.0019) were independent significant predictors ( Table 3) .
A risk model was also constructed using the three preinduction risk factors found in this multivariate analysis: liver metastasis, ECOG PS score 2 and leukocyte counts 8000/ml. Each patient was then assigned to one of the three risk groups: those with zero risk factor (favorable risk, n ¼ 57, There was a significant difference in the survival profiles of the three risk groups (P , 0.0001, Fig. 2) . Additionally, factors after induction of chemotherapy were also evaluated, and multivariate analysis revealed that a poor response for chemotherapy (stable disease or progressive disease, HR 2.778, P ¼ 0.0010) and the absence of focal treatment for metastatic lesions (HR 1.795, P ¼ 0.0420) were also significantly associated with poorer survival as well as the previously mentioned pre-induction factors (Table 4) .
DISCUSSION
Several prognostic factors have been reported among patients who underwent cisplatin-based chemotherapy. Analyzing 203 unresectable or metastatic cases who underwent MVAC chemotherapy, Bajorin et al. (9) found that Karnofsky Performance Status (KPS) ,80% and the presence of visceral metastasis were independent prognostic factors. The median survival time for patients who had zero, one or two risk factors were 33, 13.4 and 9.3 months, respectively, and this classification clearly separated the survival of these groups (P ¼ 0.0001). Similarly, von der Maase et al. (5) reported that KPS ,80%, presence of metastatic lesion, elevated alkaline phosphatase (ALP) level, number of disease sites (.3) and the presence of visceral metastases were significantly associated with poor overall survival among 405 advanced or metastatic cases with MVAC chemotherapy or GC chemotherapy. More recently, Abe et al. (10) showed that five or more chemotherapy cycles, absence of liver, bone and local recurrence, and resection of metastasis as independent significant predictors in a retrospective analysis of 48 patients with metastatic UC who underwent systemic chemotherapy.
Along with these reports, our study revealed that visceral metastasis was one of the poor prognostic factors and implied that liver metastasis was the most important predictor of poor survival among all metastatic sites, while lung metastasis was not. All 10 patients with liver metastasis died within 9.3 months from diagnosis. The median survival of eight patients who did not respond to chemotherapy was only 4.6 months (2.3 -7.2 months), and even the other two patients who achieved a partial response survived only for 9.1 and 9.3 months, respectively.
Although performance status (PS) was also detected as statistically significant in our study, there were only three patients whose ECOG PS score was 2 or more, which substantially corresponds to KPS ,80%. Moreover, as Abe et al. (10) had already mentioned, we also need to interpret this result carefully because PS could strongly correlate with several post-chemotherapeutic factors including the total number of chemotherapy and/or indication of metastasectomy (10) . However, as a predictor, that is, excluding postchemotherapeutic factors, PS remains an important independent factor.
Thus far, there have been few studies which investigated a variety of laboratory parameters. In addition to serum ALP reported by von der Maase et al. (5), the recent report by Nakagawa et al. (11) demonstrated that serum CRP and serum lactate dehydrogenase (LDH) levels were independent predictors of poorer survival, analyzing 114 patients who were treated with radical cystectomy for urothelial bladder carcinoma and subsequently developed metastases (11) . Our study has shown that leukocyte counts 8000/ml was a significant risk factor on multivariate analysis, while the elevation of ALP, LDH or CRP was not. Although such inflammatory markers are likely to be associated with survival in various cancers, the importance of these markers in urinary tract cancer remains to be established. Therefore, further investigation is needed for confirmation.
Although advanced T stage (T3) was a significant factor on the univariate analysis (log-rank test, P ¼ 0.0125*), we 
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Prognostic factors for metastatic urothelial carcinoma excluded T stage from this study, because for each T stage, there are some clinical and prognostic differences between upper urinary tract cancer and bladder cancer (12) .
Response to chemotherapy and focal treatment for metastatic lesions were also significant factors, but not predictive parameters which can only be determined after initiation of treatment. For the past 10 years, clinical evidence has accumulated suggesting the efficacy of multimodal treatment including metastasectomy. Lehmann et al. (13) showed a overall 5-year survival rate of 28% among 44 patients undergoing complete metastasectomy for UC. On the other hand, based on the observation of 276 cases who received cisplatin-based chemotherapy, Herr et al. recommended that cases with a complete or partial response to chemotherapy and cases with limited nodal or a solitary visceral metastasis are most likely to benefit from metastasectomy. The study also concluded that surgery should be avoided in cases with multiple liver metastases, as well as metastases involving more than one visceral site or abdominal organ, or bone metastases, especially involving the pelvis or axial skeleton (14, 15) . More recently, Nakagawa et al. (11) showed that patients with solitary lung metastasis, long duration from radical surgery to recurrence, no neoadjuvant/adjuvant chemotherapy, no symptom and low CRP level were most likely to benefit from metastasectomy. Our study also showed that focal treatment for metastatic lesions was a statistically significant factor for better outcome. Multi-modal treatment including metastasectomy should be considered when possible.
Along with similar previous studies, the limitation of our study is a retrospective analysis of a limited number of cases in a single institution. Confirmatory studies with larger populations may be required. In addition, our model was fit to our sample but has not been validated externally.
In conclusion, liver metastasis, poor PS and higher leukocyte counts were independent poor prognostic indicators for metastatic UC. Our risk classification (zero, one and two or three risks) enables an accurate prediction of survival which 
